OneThree Biotech completes build and optimisation of AI model for RSV data – results to come in H2
Poolbeg Pharma PLC (AIM:POLB) US patents granted for POLB 001 and POLB 002
Further expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Poolbeg Pharma PLC (AIM:POLB) GMP manufacturing contract signed
Update on POLB 001 Clinical Development
Poolbeg Pharma PLC (AIM:POLB) Attendance at European Melioidosis Congress
Poolbeg to engage with key international stakeholders at congress as it develops an intramuscular Melioidosis vaccine candidate
Poolbeg Pharma PLC (AIM:POLB) Distribution in Specie update
Results of the proposal to purchase shares from Distribution in Specie shareholders
Poolbeg Pharma PLC (AIM:POLB) Key POLB 002 European Patent Granted
Continued expansion of the POLB 002 patent family following European Patent Office approval
Poolbeg Pharma PLC (AIM:POLB) Distribution in Specie Shareholders
Proposal to Purchase Shares from Distribution in Specie Shareholders
Poolbeg Pharma PLC (AIM:POLB) POLB001 Update – Clinical Trial Agreement Signed
On track to commence LPS human challenge clinical trial in June 2022
Poolbeg Pharma PLC (AIM:POLB) Commencement of trading on US OTCQB market
Poolbeg Pharma commences trading on OTCQB Market in the United States
Poolbeg Pharma PLC (AIM:POLB) Artificial Intelligence deal signed with CytoReason
First time that AI analysis of human challenge trial data is used to identify novel drug targets for influenza
Open Orphan plc distribution in specie of Poolbeg Pharma plc shares – Q&A
Open Orphan distribution in specie shares and in particular some people had been concerned that they were unable to trade them.
Poolbeg Pharma PLC (AIM:POLB) 2021 Annual Report and 2022 AGM Notice
9 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a unique capital-light clinical model, announces that its Annual Report and